Celldex Therapeutics, Inc. 8-K

What Happened
Celldex Therapeutics, Inc. announced on April 1, 2026 that it entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC to sell 10,345,000 shares of its common stock at $29.00 per share. The Offering is expected to net the company approximately $282 million after underwriting discounts, fees and expenses, and is expected to close on or about April 6, 2026, subject to customary closing conditions. The company filed a prospectus supplement dated April 1, 2026 and issued press releases about the launch and pricing of the Offering.

Key Details

• Offering size: 10,345,000 shares of common stock priced at $29.00 per share.
• Expected net proceeds: approximately $282 million (after underwriting discounts/commissions and offering expenses).
• Overallotment: Underwriters have a 30-day option to buy up to 1,551,750 additional shares (up to 15% more) at the same price.
• Underwriters/filings: Agreement with Leerink Partners LLC and TD Securities (USA) LLC; prospectus supplement filed April 1, 2026; legal opinion of Lowenstein Sandler LLP included as an exhibit.

Why It Matters
This transaction will raise material capital for Celldex and will increase the number of outstanding shares, which dilutes existing shareholders to the extent shares are issued. The potential 30-day overallotment could increase the offering by up to 15%. The Offering’s closing is subject to customary conditions and forward-looking risks described in the company’s SEC filings (including its Feb 25, 2026 Form 10-K). Investors should monitor the closing, final share count if the overallotment is exercised, and subsequent disclosures about the company’s use of proceeds.